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ABSTRACT
Purpose: The aim of this study was to investigate
whether expression of particular drug resistance genes in
primary operable breast cancer correlates with response to
first-line chemotherapy in advanced disease.
Experimental Design: We determined mRNA levels of
BCRP, LRP, MRP1, MRP2, and MDR1 in 59 primary breast
tumor specimens of patients who received chemotherapy as
first-line systemic treatment after diagnosis of advanced
disease. The relative expression levels were measured by
quantitative real-time reverse transcription-PCR and sub-
sequently analyzed in relation to the type of response to
chemotherapy, the length of progression-free survival (PFS),
and post-relapse overall survival.
Results: For each of these drug resistance genes, a large
variation in expression level was observed among the tumors
of the different patients. When analyzing mRNA expression
in relation to overall response, it was found that the median
expression level of these five drug resistance genes in the
responding tumors, as compared with nonresponding tu-
mors, was markedly lower. Classification of tumors as high
versus low with respect to the expression level of these genes
showed that the overall response in the MDR1-high subset
(17%), as compared with the MDR1-low subset (68%), was
significantly lower (P  0.005). Although similar differences
in response rate were found for subsets of tumors stratified
by the expression level of the other drug resistance genes,
none of the observed differences were statistically signifi-
cant. However, in the subgroup of patients treated with
anthracycline-based chemotherapy (5-fluorouracil, Adria-
mycin/epirubicin, and cyclophosphamide), a correlation
between response and the expression of BCRP and MRP1
(only PFS) was found, whereas such an association was
not present in the cyclophosphamide, methotrexate, and
5-fluorouracil-treated group of patients. Furthermore, high
expression of LRP as well as MDR1 was found to be signif-
icantly associated with a poor PFS (P  0.04 and P < 0.001,
respectively). For lung resistance-related protein, this asso-
ciation was limited to 5-fluorouracil, Adriamycin/epirubicin,
and cyclophosphamide. Expression levels of BCRP, MRP1,
or MRP2 were not related with the length of PFS. Further-
more, no correlation between the expression level of these
drug resistance genes and post-relapse overall survival was
found.
Conclusions: In this pilot study, MDR1 expression in
primary breast tumors was inversely related with the effi-
cacy of first-line chemotherapy, and high expression level
was a significant predictor of poor prognosis for patients
with advanced disease. Apart from MDR1, the expression
levels of BCRP, LRP, and MRP1 might have some additional
predictive value for clinical outcome.
INTRODUCTION
Chemotherapy is the treatment of choice for patients with
ER2-negative and hormone-refractory breast cancer (reviewed
in Refs. 1 and 2). Traditional chemotherapy regimens for the
treatment of advanced breast cancer consisted of cyclophos-
phamide, MTX, 5-fluorouracil, prednisone, and vincristine com-
binations (3). Later on, anthracycline-based chemotherapy has
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gradually become the standard in the treatment of advanced
breast cancer. Anthracyclines such as doxorubicin (Adriamycin)
and its analogue epirubicin are considered as highly active
anticancer agents, which are commonly used in combinations
with 5-fluorouracil and cyclophosphamide (FAC/FEC) in the
treatment of breast cancer. Even though breast cancer is often
considered as one of the more chemosensitive solid tumors, all
initially responsive tumors relapse and develop resistance to a
broad spectrum of drugs known as MDR. Consequently, meta-
static breast cancer finally becomes refractory to cytotoxic drugs
and is typically incurable by chemotherapy (3). Thus, intrinsic
or acquired drug resistance is primarily responsible for the
failure of current treatment regimens in metastatic breast cancer
(4). Despite comprehensive knowledge on in vitro mechanisms
of drug resistance, the precise nature of this in vivo MDR
phenotype in breast cancer is still unclear.
One of the mechanisms of drug resistance in cancer cells is
associated with altered anticancer drug transport, mediated by
members of the ABC superfamily of transport proteins (5) such
as MDR1 (6) and the MRPs (7). P-gp, the product of MDR1,
was the first anticancer drug pump to be identified (8). The
MDR phenotype conferred by overexpression of MDR1 is char-
acterized by resistance to structurally unrelated cytotoxic agents,
including anthracyclines (doxorubicin and epirubicin are among
the most effective anticancer drugs used in the treatment of
breast cancer), epipodophyllotoxins, Vinca alkaloids, and tax-
anes (9). Thus, increased expression of MDR1 is likely to
contribute to clinical drug resistance in breast cancer.
Another ABC membrane transport protein implicated in
clinical drug resistance and capable of actively decreasing the
intracellular drug concentration in functional in vitro assays is
MRP1 (10). Vesicular transport experiments have shown that
the preferred substrates for MRP1 are drugs conjugated to
glutathione, glucoronate, or sulfate and various other organic
anions including MTX (reviewed in Refs. 7 and 11). Transfec-
tion studies established that MRP1 overexpression confers re-
sistance to a wide variety of anticancer agents, including an-
thracyclines, vincristine, and epipodophyllotoxins. Thus, MRP1
expression may affect clinical outcome of chemotherapy in
metastatic breast cancer. MRP2, originally known as the canal-
icular multispecific organic anion transporter (cMOAT), is an-
other member of the MRP family that may play a role in the
MDR phenotype of cancer cells (7). The whole spectrum of
MRP2 substrates has not been completely defined, but it has
been reported that MRP2 confers resistance to several antican-
cer agents, including MTX, cisplatin, vinblastine, and campto-
thecin derivatives (7). Thus, MRP2 may have a role in clinical
drug resistance of breast cancer treated with MTX-containing
chemotherapeutic regimens.
Recently, a novel ABC half transporter, BCRP, was iden-
tified as a drug efflux pump for anticancer drugs, including
topoisomerase I and II inhibitors (12). To date, BCRP expres-
sion has hardly been studied in human cancers, and thus far no
data are available correlating its expression with the efficacy of
chemotherapy regimens in breast cancer. Because BCRP can
confer cellular resistance to doxorubicin and epirubicin, it may
play a role in the drug resistance phenotype of breast cancer.
In addition to an overall reduction of intracellular drug
concentration, associated with overexpression of ABC transport
proteins, a redistribution of the drug from the nucleus to the
cytoplasm has also been implicated in MDR of cancer cells (13).
It has been reported that LRP, as an integral part of the vault
complex, is involved in the intracellular distribution of chemo-
therapeutic agents (14, 15). Moreover, LRP overexpression was
found to be associated with redistribution of doxorubicin from
the nucleus to the cytoplasm of colon carcinoma cells (16).
Clinical data indicate that this LRP protein is often expressed in
human malignancies and that its expression may be associated
with poor response to chemotherapy in ovarian carcinoma and
AML (14, 15). Although studies on LRP expression in breast
cancer are limited, it has been reported that LRP protein is
frequently expressed in primary breast carcinoma (17).
In the present study, we investigated the expression of a
number of drug resistance genes in breast cancer and examined
whether the expression levels correlated with clinical outcome.
Therefore, mRNA levels of BCRP, LRP, MRP1, MRP2, and
MDR1 were determined in primary operable breast tumor tis-
sues of patients who, upon relapse, were treated with systemic
first-line chemotherapy. The level of mRNA expression was
determined by quantitative real-time RT-PCR and subsequently
analyzed in relation to the type of response on chemotherapy,
the length of PFS, and PR-OS.
MATERIALS AND METHODS
Patients and Tumors. A total of 59 patients with pri-
mary operable breast cancer who underwent resection of their
primary tumors between 1985 and 1995 were included in this
study. The resected primary tumor tissues were kept in liquid
nitrogen. The patient and tumor characteristics, gathered from
the pathology reports, are listed in Table 1 (information on
histological grade was missing for some patients). ER and PgR
levels were determined in primary tumor cytosols as described
previously (18). The cutoff point used to classify tumors as ER
and PgR positive was 10 fmol receptor protein/mg cytosol
protein.
Of the 59 patients, 30 (51%) received some form of adju-
vant therapy (18 received endocrine therapy, 11 received che-
motherapy, and 1 received combination chemo-endocrine ther-
apy). At the start of chemotherapy for advanced disease, the
median age of the patients was 49 years (range, 28–74 years).
Of the 59 patients with advanced disease, 28 were treated with
CMF, whereas the other 31 patients received anthracycline-
based chemotherapy (FAC/FEC). Type of response to systemic
treatment was defined by the standard Union International Con-
tre Cancer criteria as described previously (19). Accordingly,
objective response is CR plus partial response. Patients with no
change for more than 6 months were defined as having pro-
longed SD, whereas patients with PD or with SD with progres-
sion within 6 months (SD  6 months) were classified as
nonresponders. Hence, 22 of the 59 patients (37%) showed an
objective response [CR, n  3; PR, n  19), and 12 patients
(20%) had prolonged SD (no change for 6 months), whereas
25 patients (42%) did not respond (PD, n  14; SD with
progression within 6 months, n  11) to the chemotherapeutic
treatment. Thus, the overall response rate, defined as objective
response (n  22) plus prolonged SD (n  12), was found to be
58% (34 of 59 patients). At the time of analysis, 51 patients
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(86%) had died, whereas 8 patients were still alive with a
median follow-up of 64 months (range, 13–105 months). During
follow-up after start of chemotherapy, 55 (93%) of the patients
had disease progression, with a median time to progression of 6
months (range, 1–26 months). Of these patients, 25 were even-
tually treated with endocrine therapy immediately after progres-
sion on first-line chemotherapy, and 10 of these patients re-
ceived endocrine therapy after one or two additional
chemotherapy regimens.
RNA Isolation and cDNA Synthesis. Total RNA was
isolated from three 15-m cryostat sections of frozen breast
cancer biopsies using the RNazol B extraction method (Campro
Scientific, Veenendaal, the Netherlands) according to the man-
ufacturer’s instructions (TEL-Test Bulletin No. 2). An addi-
tional cryostat section was used to determine the content of
tumor cells. For all breast cancer samples included in the anal-
yses, the number of tumor cells represented at least 50% of total
nucleated cells (range, 50–90%; median, 70%), as judged by
H&E staining of the sections. Tumor sample RNA was diluted
in DEPC-treated RNase-free ultra-pure water (DEPC; Sigma-
Aldrich, Zwijndrecht, the Netherlands) and stored at 80°C.
Total RNA (3 g) was reverse transcribed for 1 h at 37°C in a
50-l volume of 1 first strand buffer containing 250 units of
Superscript II RNase H reverse transcriptase, 15 units of
RNAseOUT recombinant RNase inhibitor, and 1 mM DTT (all
from Life Technologies, Inc.), further supplemented with de-
oxynucleoside triphosphates (1 mM each), 1.5 g of pd(T)12–18
oligo(dT) primer, and 1.5 g of pd(N)6 random hexamer (all
from Amersham Pharmacia Biotech Benelux, Roosendaal, the
Netherlands). The resulting cDNA was diluted in ultra-pure
water and aliquoted at 80°C. Forty ng of cDNA diluted in a
10-l volume of DEPC-treated RNase-free ultra-pure water
were used in each real-time amplification reaction.
Quantitative Real-time RT-PCR. The mRNA levels of
BCRP, LRP, MRP1, MRP2, and MDR1 were measured by
real-time RT-PCR based on TaqMan chemistry and quantitated
using an ABI PRISM 7700 sequence detector system (Applied
Biosystems, Foster City, CA). In addition, the mRNA levels of
two internal control genes, i.e., GAPDH and PBGD, were meas-
ured and used to normalize the mRNA levels of the drug
resistance genes. PCR products were detected using a dual-
fluorescent nonextendable probe containing a 5 FAM (6-
carboxy-fluorescein) reporter dye and a 3 TAMRA (6 carboxy-
tetramethylrhodamine) quencher dye for all reactions, except for
the GAPDH reaction, in which FAM was substituted by VIC.
The GAPDH mRNA levels were measured using the Pre-devel-
oped TaqMan Assay Reagents for human GAPDH (Applied
Biosystems). All other primer pairs, in conjunction with their
appropriate fluorescent hybridization probes (sequences are
given in Table 2), were designed by Oligo 6.0 primer analysis
software (Medprobe, Oslo, Norway) and purchased by Oswel
Research Products (Eurogentec, Seraing, Belgium). Notably, the
primers and probe sets were designed to amplify across an
intron/exon boundary, thereby preventing amplification of re-
sidual genomic DNA. Real-time PCR was performed in dupli-
cate reactions of 50 l of 1 TaqMan buffer A (Applied
Biosystems) containing 40 ng of tumor sample cDNA as a
template. PCR was performed in the presence of 300 nM forward
and reverse primers, 200 nM probe, 250 M deoxynucleoside
triphosphates, 1.25 units of AmpliTaq Gold DNA polymerase,
and 4 mM MgCl2. Samples were heated for 2 min at 50°C and
10 min at 95°C, followed by 50 cycles of amplification for 15 s
at 95°C and 1 min at 60°C. Under these assay conditions, a
linear relation was noted for log amount of cDNA from MCF-7,
an established breast cancer cell line. Furthermore, serial diluted
cDNA prepared from pooled RNA of four leukemia cell lines
(CEM, K562, and two EBV-induced lymphoblastoid B-cell
lines) was used as an additional positive control. The PCR
efficiencies of the five target genes and the two endogenous
reference genes were comparable (95%).
To compare the expression levels among different tumor
samples, the relative expression level of the resistance genes
was calculated using the comparative CT method and compared
with a calibrator (20, 21). The comparative CT method elimi-
nates the use of standard curves for relative quantitation as long
as the PCR efficiency of target and reference gene is similar.
Briefly, reactions are characterized by comparing CT values.
Table 1 Patient and tumor characteristicsa
Characteristic No. (%)
All patients 59
Age at start of therapy (yrs)
40 12 (20)
40–55 28 (47)
55–70 17 (29)
70 2 (3)
Menopausal status at start of therapy
Premenopausal 31 (53)
Postmenopausal 28 (47)
T status
pT1 12 (20)
pT2 39 (66)
pT3/4 8 (14)
Nodal status
N0 18 (31)
N1–3 14 (24)
N3 26 (44)
Unknownb 1 (2)
Histological grade
Poor 37 (63)
Good/moderate 3 (5)
Unknownb 19 (32)
ER statusc
Negative 30 (51)
Positive 29 (49)
PgR status
Negative 31 (53)
Positive 28 (47)
DFI
12 mo 26 (44)
12 mo 33 (56)
First site of relapse
Soft tissue 7 (12)
Skeletal 16 (27)
Visceral 36 (61)
Adjuvant treatment
No 29 (49)
Yes 30 (51)
a Patients and tumor characteristics are detailed in “Materials and
Methods.”
b Information on nodal status and histological was not available for
some patients.
c Cut point used: 10 fmol/mg protein.
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The CT value is defined as the fractional cycle number at which
the emitted sample fluorescence passes a fixed threshold above
the baseline. The CT value is defined as the difference in CT
value for the target and reference gene(s). Accordingly, CT 
(mean target gene CT) – [(the mean of duplicate CT values for
GAPDH 	 the mean of duplicate CT values for PBGD)/2]. The
relative gene expression in a particular sample, normalized to
GAPDH and PBGD and compared with the expression of that
target gene in a calibrator, is then given by the following:
relative amount of target  2CT value. The CT value in
this formula is defined as the CT value of the target gene for
a particular sample less the CT value of that target gene for a
calibrator (CT  CT(target)  CT(calibrator)). In this study,
the calibrator was a cDNA pool from normal peripheral WBCs.
We have used the average CT value of two endogenous refer-
ence genes instead of a single one to correct for tumor sample-
specific variation in housekeeping gene expression. Notably,
tumor samples with an aberrant GAPDH:PBGD ratio were
omitted from the analysis.
Statistical Analysis. The associations between expres-
sion levels of BCRP, MRP1, MRP2, LRP, and MDR1 and
their relationship with age and PgR and ER levels were
studied with Spearman rank correlation (rs). The strength of
the association between the expression levels of the drug
resistance genes (treated as continuous variables) and other
patient and tumor characteristics and DFI (treated as group-
ing variables) was tested with the Mann-Whitney U test or
the Kruskal-Wallis test. In an exploratory analysis to search
for optimized cut points to classify tumors as high versus low
for the respective factor, isotonic regression analysis (22)
was used with the overall response rate as end point. PFS and
PR-OS probabilities were calculated by the actuarial method
of Kaplan and Meier (23). Response was analyzed with
logistic regression. PFS and PR-OS were analyzed using the
Cox proportional hazards model. The length of PFS was
defined as the time from the start of treatment of advanced
disease until the time of PD or intercurrent death, and dif-
ferences in PFS were assessed by the log-rank test. All
statistical analyses were performed with Stata Statistical
Software (release 7.0; Stata Corp., College Station, TX).
RESULTS
Expression of Drug Resistance Genes in Breast Cancer.
The mRNA expression levels of BCRP, LRP, MRP1, MRP2,
and MDR1, estimated by real-time RT-PCR, were expressed in
arbitrary units for all 59 individual primary tumor samples (Fig.
1, A-E). A marked variation in expression level was found for
each of these genes, and the estimated relative mRNA expres-
sion levels showed an approximately log-normal distribution.
The median relative expression levels were 177 (range, 24–
2065) for BCRP, 111 (range, 6–729) for LRP, 85 (range,
11–784) for MRP1, 59 (range, 0.5–1123) for MRP2, and 8.8
(range, 0.5–84.8) for MDR1.
Subsequent analysis with regard to potential interrelationships
of these drug resistance genes revealed that the mRNA levels of
BCRP were positively related with those of LRP (rs  0.42; P 
0.001), MRP1 (rs  0.37; P 0.005), and MDR1 (rs  0.69; P
0.0001). In addition, the levels of LRP were positively related with
those of MRP1 (rs  0.46; P  0.001), MRP2 (rs  0.36; P 
0.007), and MDR1 (rs  0.36, P  0.006). Furthermore, MRP1
expression levels were positively related with those of MRP2 (rs 
0.30; P  0.024) and MDR1 (rs  0.51; P  0.0001). Next we
investigated the mRNA expression of these genes in relation to
traditional clinical prognostic factors as listed in Table 1. Only
weak correlations were found with ER, PgR, and DFI. The expres-
Table 2 Sequences of primer and probes set
BCRP 235-bp amplicon
Forward primer 5-TGGCTGTCATGGCTTCAGTA-3
Reverse primer 5-GCCACGTGATTCTTCCACAA-3
Probe 5-AGCAGGGCATCGATCTCTCACCCTG-3
LRP 68-bp amplicon
Forward primer 5-CAGCTGGCCATCGAGATCA-3
Reverse primer 5-TCCAGTCTCTGAGCCTCATGC-3
Probe 5-CAACTCCCAGGAAGCGGCGGC-3
MRP1 65-bp amplicon
Forward primer 5-CAATGCTGTGATGGCGATG-3
Reverse primer 5-GATCCGATTGTCTTTGCTCTTCA-3
Probe 5-AGACCAAGACGTATCAGGTGGCCCAC-3
MRP2 219-bp amplicon
Forward primer 5-ATGCTTCCTGGGGATAAT-3
Reverse primer 5-TCAAAGGCACGGATAACT-3
Probe 5-TGTATCTGTTCAGATGTTTTATGTGTCTACCT-3
MDR1 195-bp amplicon
Forward primer 5-GGAAGCCAATGCCTATGACTTTA-3
Reverse primer 5-GAACCACTGCTTCGCTTTCTG-3
Probe 5-TGAAACTGCCTCATAAATTTGACACCCTGG-3
PBGD 98-bp amplicon
Forward primer 5-CTGCACGATCCCGAGACTCT-3
Reverse primer 5-GCTGTATGCACGGCTACTGG-3
Probe 5-CTGAGGCACCTGGAAGGAGGCTG-3
GAPDHa
a The GAPDH primer set and the corresponding fluorogenic probe were designed by and purchased from Applied Biosystems.
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sion levels of BCRP and LRP were found to be positively corre-
lated with those of ER [rs  0.32 (P  0.014) and rs  0.38 (P 
0.003), respectively] and PgR [rs 0.30 (P 0.021) and rs 0.31
(P  0.017), respectively]. In addition, low MDR1 and MRP1
mRNA levels were both associated with a prolonged DFI with
respective Ps of 0.036 and 0.018.
Response to Chemotherapy and Correlation with Ex-
pression. The objective response rate of the patients included
in these analyses was 37% (22 of 59 patients), and the overall
response rate was 58% (34 of 59 patients). Within this cohort of
59 patients, the type of response to chemotherapy was not
significantly related to any of the clinicopathological patient and
tumor parameters listed in Table 1.
When analyzing BCRP, LRP, MRP1, MRP2, and MDR1
as log-transformed continuous variables, there were no statisti-
cally significant associations with the overall response rate.
However, comparing the tumors of responding versus nonre-
sponding patients with respect to the relative expression levels
of these genes showed that tumors of responding patients had
the lowest median expression levels for BCRP (174 versus 255),
LRP (108 versus 119), MRP1 (83 versus 95), MRP2 (32 versus
79), and MDR1 (7 versus 17). Therefore, in an exploratory
analysis, we used isotonic regression analysis (22) with the
overall response rate as end point to search for optimized cut
points to classify tumors as high versus low for the respective
factor. The resulting cut points chosen were BCRP  360,
LRP  152, MRP1  85, MRP2  59, and MDR1  26.
The overall response rates for the subgroups of patients
classified as high versus low for the different drug resistance
genes are shown in Table 3. Although tumors with high mRNA
expression levels of BCRP, LRP, MRP1, or MRP2 showed a
lower overall response rate as compared with tumors with low
mRNA levels, none of the observed differences was statistically
significant. In contrast, for MDR1, a significant inverse corre-
lation was found between expression level and overall response
rate. Only 2 of 12 patients (17%) with a high MDR1 expression
responded, compared with 32 of 47 patients (68%) with a low
MDR1 level (odds ratio, 0.09; 95% CI, 0.02–0.48; P  0.005).
Expression Levels in Relation to PFS and PR-OS. The
expression levels of the drug resistance genes were further
analyzed in relation to the length of PFS and PR-OS. Kaplan-
Meier curves, stratified by expression of the respective drug
resistance genes, revealed that BCRP (Fig. 2A), MRP1 (Fig.
2C), or MRP2 (Fig. 2D) status was not significantly related with
the length of PFS. However, high expression levels of LRP or
MDR1 were found to be significantly associated with a poor
PFS (Fig. 2, B and E, respectively). The RHR for high (as
compared with low) LRP expression was 1.85 (95% CI, 1.04–
3.30; P  0.04), and for high MDR1 expression, the RHR was
4.22 (95% CI, 1.95–9.15; P  0.001). A significant correlation
between the level of mRNA expression and the length of PR-OS
was not found for any of the investigated drug resistance genes
(data not shown).
Anthracycline-based Chemotherapy (FAC/FEC) versus
CMF. The breast cancer patients included in this study re-
ceived either anthracycline-based chemotherapy (FAC/FEC) or
CMF as first-line treatment for metastatic disease. Therefore, we
further analyzed mRNA expression of BCRP, LRP, MRP1,
MRP2, and MDR1 in relation to clinical outcome for these
distinct regimens. Furthermore, no significant difference was
seen in the overall response rates between CMF-treated (54%)
and FAC/FEC-treated patients (61%). However, classification
of tumors into high and low with respect to expression of the
drug resistance genes showed different response rates for CMF
and FAC/FEC (Table 3). For all drug resistance genes except
Fig. 1 Relative mRNA expression levels of BCRP (A), LRP (B), MRP1
(C), MRP2 (D), and MDR1 (E), as estimated by real-time RT-PCR and
expressed in arbitrary units (a.u.), are shown for all individual primary
breast tumor samples. Expression data were available for all 59 tumor
samples, except for MRP2, where expression data of patients 1, 4, and
27 are missing. Insets show the log-normal distribution.
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MRP2, we found a trend that higher levels of mRNA expression
were related with poor response in FAC/FEC-treated patients,
whereas no such relation was seen in the subgroup of CMF-
treated patients. The difference in response rate between high
and low expression for tumors that received anthracycline-based
chemotherapy was found to be statistically significant for
MDR1 (P  0.001) and borderline significant for BCRP (P 
0.056). Notably, in the FAC/FEC subset, 0 of 6 MDR1-high
tumors responded, whereas 19 of 25 (76%) MDR1-low tumors
responded to this type of chemotherapy. Unlike the FAC/FEC-
treated tumors, the level of MDR1 expression was not related
with the rate of response in the CMF-treated subgroup of pa-
tients.
Next we analyzed the expression levels of the drug resist-
ance genes in relation to the length of PFS for these two distinct
chemotherapeutic regimens (Fig. 3). The length of PFS in rela-
tion to type of chemotherapy (CMF versus FAC/FEC) was
identical (P  1.0; Kaplan-Meier curves not shown). However,
a clear difference in the length of PFS between high- and
low-expressing tumors was seen for BCRP (Fig. 3B; not signif-
icant), LRP (Fig. 3D, P  0.04), and MRP1 (Fig. 3F, P  0.04)
in the FAC/FEC-treated tumors, but not in those treated with
CMF (Fig. 3, A, C, and E). No difference in PFS was observed
for these two treatment modalities after stratification for MRP2
expression (data not shown). With respect to MDR1, we found
that in both the FAC/FEC-treated subgroup (Fig. 3H) and the
CMF-treated subgroup of patients (Fig. 3G), high levels of
expression were significantly correlated with a shorter PFS.
However, it should be noted that the RHR of the MDR1-high
subgroup compared with the MDR1-low subgroup is higher in
the FAC/FEC-treated patients (Fig. 3H) as compared with the
CMF-treated subgroup (Fig. 3G).
DISCUSSION
Chemotherapy resistance is a major problem in the man-
agement of patients with breast cancer. In general, breast cancer
is considered to be one of the more chemosensitive solid tumors,
and major response rates (20–80%) in patients with metastatic
disease have been reported (2). However, CRs are rare, and most
of the initially responsive tumors relapse and develop resistance
to multiple anticancer agents of different structure and function,
a phenomenon known as MDR. Eventually, metastatic breast
cancer becomes refractory to standard combination chemother-
apy (CMF or FAC/FEC). The nature of this chemotherapy
resistance in breast cancer and the potential role of drug resist-
ance genes involved in transport or sequestration of anticancer
agents are still unclear (4). A better understanding of the mecha-
nisms(s) of chemotherapy resistance in breast cancer and further
knowledge about the genes whose expression affects the out-
come of chemotherapy in advanced disease may open the way
for specific pharmacological intervention with reversal agents to
circumvent therapy resistance (24). The aim of the present study
was to investigate whether the expression of BCRP, LRP,
MRP1, MRP2, and MDR1, genes potentially involved in trans-
port or redistribution of anticancer agents, is correlated with
clinical outcome.
We have developed and validated real-time RT-PCRs for
these five genes to quantitate their mRNA levels in primary
breast tumors. Whereas commonly used methods such as RNase
protection and, in particular, immunohistochemistry fail to de-
tect low-abundance expression, the detection threshold of fluo-
rescence-based kinetic RT-PCR enables us to detect and distin-
guish very low-level mRNA expression (25). Here, we showed
that (low abundance) mRNA expression of these five genes was
readily detected and that small differences in mRNA levels
obtained from limited frozen tissue could be reproducibly quan-
titated. Significant positive correlations between the mRNA
levels of drug resistance genes were found, particularly for
MDR1/BCRP, MDR1/MRP1 and LRP/MRP1, and may indicate
that the expression of these genes is likely to be coordinately
regulated. Similar correlations between the expression of these
genes were observed previously (26, 27). Moreover, MDR1,
MRP1, and LRP were significantly correlated with the protein
kinase C
 isozyme (26), which in turn has been reported to
transcriptionally regulate the MDR1 promoter (28). Thus, pro-
tein kinase C
 could represent a key regulator factor for up-
regulation of various MDR-associated genes.
To investigate the clinical significance of BCRP in breast
Table 3 Expression in relation to overall response to chemotherapy and for FAC/FEC and CMF separatelya
Subset of patientsb
Chemotherapy (all) CMF FAC/FEC
R/Nc (%) [OR; 95% CI; P] R/N (%) [P] R/N (%) [P]
All patients (n  59) 34/59 (58) 15/28 (54) 19/31 (61) [P  0.55]
BCRP-low 27/42 (64) 11/20 (55) 16/22 (73)
BCRP-high 7/17 (41) [0.39; 0.12–1.23; P  0.11] 4/8 (50) [P  1.0] 3/9 (33) [P  0.056]
LRP-low 24/37 (65) 10/17 (59) 14/20 (70)
LRP-high 10/22 (45) [0.45; 0.15–1.33; P  0.15] 5/11 (45) [P  0.70] 5/11 (45) [P  0.26]
MRP1-low 18/30 (60) 8/16 (50) 10/14 (71)
MRP1-high 16/29 (55) [0.82; 0.29–2.31; P  0.71] 7/12 (58) [P  0.66] 9/17 (53) [P  0.30]
MRP2-low 18/28 (64) 5/8 (63) 13/20 (65)
MRP2-high 13/28 (46) [0.48; 0.16–1.41; P  0.18] 8/18 (44) [P  0.40] 5/10 (50) [P  0.43]
MDR1-low 32/47 (68) 13/22 (59) 19/25 (76)
MDR1-high 2/12 (17) [0.09; 0.02–0.48; P  0.005] 2/6 (33) [P  0.37] 0/6 (0) [P  0.001]
a The overall response rate was defined as objective response (CR 	 PR) plus SD ( prolonged ‘’no change’).
b Cut points used were as described in Fig. 2. Three MRP2 data points were missing for analysis because the expression levels of the respective
tumors were not available.
c R/N, number of responders/total number of patients.
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cancer, we compared BCRP mRNA levels with those of LRP,
MRP1, MRP2, and MDR1. Although advanced breast cancer
patients with BCRP-high primary tumors had a lower response
rate to first-line chemotherapy (Table 3) together with a trend
toward a poor PFS in patients with BCRP-high tumors as
compared with BCRP-low tumors (Fig. 2A), these differences
were not statistically significant. From these data, we concluded
that BCRP expression had no or only limited power to predict
response to first-line chemotherapy in our studied cohort of
advanced breast cancer patients. To date, BCRP expression has
hardly been studied in human cancers, and thus far, only two
exploratory studies in AML have been conducted to evaluate the
clinical significance of BCRP expression (29, 30). No clear
correlation between BCRP expression and response to subse-
quent treatment was found in AML, and, similar to our results,
BCRP expression was correlated with that of MDR1. Based on
the substrate specificity of BCRP, a more prominent correlation
between expression and clinical outcome could be expected in
the subgroup of patients with advanced disease who received
anthracycline-containing regimens. Indeed, we found that the
negative correlation between BCRP mRNA expression and re-
sponse rate (Table 3) as well as PFS (Fig. 3, A and B) was
stronger in the FAC/FEC-treated subgroup, as compared with
CMF-treated patients. This might suggest that anthracyclines are
actively exported from breast cancer cells by BCRP and that its
expression in primary breast tumors has some predictive value
in relation to clinical outcome of anthracycline-based chemo-
therapy. Hence, the putative predictive value of BCRP expres-
sion seems to be exclusive for anthracycline-based chemother-
apy. In contrast, two studies showed a lack of correlation
between BCRP mRNA expression and response to anthracy-
cline-based chemotherapy (27, 31). Moreover, Kanzaki et al.
(27) reported that BCRP mRNA levels, as determined by semi-
quantitative RT-PCR, were very low and hardly varied among
individual tumors. This discrepancy may be explained by dif-
ferences in detection threshold of the used methodologies (i.e.,
highly sensitive and quantitative TaqMan chemistry versus
semiquantitative RT-PCR). In accordance with our study,
Faneyte et al. (31) showed that BCRP expression in clinical
breast cancer samples, which was not detectable with immuno-
histochemistry, was clearly detected by real-time RT-PCR and
varied widely. Also in that particular study, there was no clear
indication that elevated BCRP expression in breast carcinomas
conferred resistance to anthracyclines. The results of our present
study warrant more extensive investigations on the role of
BCRP in chemotherapy resistance of breast cancer.
With respect to LRP, we found in our study a statistically
significant correlation between the expression level and length
of PFS (Fig. 2B). Because this correlation was not found for the
subgroup treated with CMF (Fig. 3C), our results suggest that
LRP may play a role in anthracycline resistance. It has been
reported that enhanced LRP protein expression in colon carci-
noma cells was associated with redistribution of doxorubicin
from the nucleus to the cytoplasm (16). With regard to the
clinical significance of LRP expression in breast carcinoma, it
has been reported that LRP protein expression in locally ad-
vanced breast cancer was found to be associated with the pres-
ence of axillary nodal metastasis after induction chemotherapy,
suggesting that LRP may play a role in the resistance phenotype
of intrinsically resistant clones that persist after induction chem-
otherapy (32). On the other hand, several other breast cancer
studies reported a lack of correlation between LRP expression
and clinical outcome (33–35). It should be noted that in these
latter (negative) studies, LRP expression was determined by
Fig. 2 Kaplan-Meier curves for PFS as a function of the relative
mRNA levels of BCRP (A), LRP (B), MRP1 (C), MRP2 (D), and MDR1
(E). The optimized cut points to classify tumors as high versus low for
BCRP, LRP, MRP1, MRP2, and MDR1 were 360, 152, 85, 59,
and 26, respectively. The number of patients at risk in each group at
different time points is shown.
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immunohistochemistry, which has a rather low detection thresh-
old as compared with the TaqMan technology. Although com-
pelling evidence has not been provided yet, our exploratory
study indicates that LRP expression in primary breast cancer
may have some predictive power with respect to clinical
outcome.
It has been reported that MRP2 confers in vitro resistance
to MTX, which is used in the CMF treatment of advanced breast
cancer (7). However, we showed that the level of MRP2 expres-
sion had no relationship whatsoever with the efficacy of CMF
treatment in advanced breast cancer, suggesting that MRP2 has
no major role in clinical drug resistance of breast cancer. With
respect to MRP1, we found that the level of expression was only
related to clinical outcome in the subgroup of patients treated
with anthracycline-based chemotherapy, and not in the CMF
subgroup. Although hyperexpression of MRP1 has been ob-
served in several human cancers, including non-small cell lung
cancer, esophagus squamous cell carcinoma, and several types
of leukemia (36–38), comprehensive evidence about the signif-
icance of MRP1 expression in clinical resistance of these human
cancers is still lacking. Previously, we reported that MRP1
might play a role in clinical chemotherapy resistance in breast
cancer (39, 40). There, it was concluded that MRP1 protein
expression is a predictor of poor prognosis in breast cancer
patients who received chemotherapy as first-line systemic treat-
ment for recurrence (39). Furthermore, MRP1 might be of
prognostic significance in the subgroups of patients with a more
favorable prognosis, i.e., node-negative patients with relatively
small tumors, as well as in the setting of adjuvant systemic
chemotherapy (40). The data as presented here suggest that the
clinical role of MRP1 in chemotherapy resistance of breast
cancer might be restricted to anthracycline resistance because
MRP1 expression had no effect on clinical outcome of CMF-
treated patients (Fig. 3, E and F).
Here, we demonstrated the clinical significance of MDR1
expression in primary breast tumors. Evaluation of the literature
with respect to MDR1 expression in breast cancer revealed that,
despite numerous reports, there is no consensus about the actual
level of expression and the clinical significance of MDR1 hy-
perexpression. It is therefore not clear whether MDR1 expres-
sion affects the efficacy of chemotherapy in breast cancer. The
inconsistency about this subject in the literature is likely due to
the lack of a sensitive and highly quantitative methodology to
assess the MDR1 expression levels. MDR1 was mostly deter-
Fig. 3 PFS as a function of the
relative mRNA levels of BCRP
(A and B), LRP (C and D),
MRP1 (E and F), and MDR1 (G
and H) in CMF- and FAC/FEC-
treated patients. For cut points,
see the Fig. 2 legend.
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mined by immunohistochemistry (reviewed in Ref. 41). Further-
more, MDR1 mRNA is generally expressed at very low levels in
breast carcinoma cells, and consequently, P-gp expression is too
low to be accurately quantitated by rather insensitive immuno-
histochemical methods or semiquantitative RT-PCR (41–43).
Although the MDR1 expression in the present study was also
low, we showed by real-time RT-PCR that MDR1 mRNA levels
of individual tumors varied markedly (100-fold range). Further-
more, we demonstrated that MDR1 expression was a statistically
significant predictor for the type of response to chemotherapy
and the length of PFS in our cohort of advanced breast cancer
patients. Taken together, our results suggest that MDR1 expres-
sion in primary breast tissue is an important predictor of clinical
outcome for patients with advanced disease receiving chemo-
therapy as first-line treatment. Notably, in a multivariable anal-
ysis adjusted for adjuvant therapy, dominant site of relapse, and
relapse-free interval, MDR1 expression was found to be an
independent predictor for response. This conclusion is in line
with the outcome of a combined review and large meta-analysis
of data from MDR1 assessment of more than 1200 breast tumors
(44). Although the individual studies showed considerable het-
erogeneity, the final conclusion of this meta-analysis was that it
seems likely that MDR1 expression in breast cancer is associ-
ated with a poor response rate to chemotherapy.
Our results suggest that in addition to MDR1, the drug
resistance-associated genes BCRP, LRP, and MRP1, but not
MRP2, may also play a role in the chemotherapy resistance of
breast cancer. Interestingly, we noted that this association be-
tween expression and clinical outcome was stronger in (MDR1),
limited to (LRP), or solely present in (BCRP and MRP1) the
subgroup of FAC/FEC-treated patients. Therefore, elevated ex-
pression of BCRP, LRP, MRP1, and MDR1 in breast tumor
tissue might be associated with anthracycline resistance.
It has been suggested that MDR1 expression is merely a
measure of malignancy or advanced disease, rather than an
indicator of chemotherapy resistance. Pursuing this thought
further, it is reasonable to expect that MDR1 expression has an
apparent effect on clinical outcome of both FAC/FEC- and
CMF-treated tumors, reflecting respectively the functional drug
efflux pump activity of P-gp and its function as a surrogate
marker for a more aggressive tumor cell behavior. Furthermore,
we found that a high MDR1 expression was correlated with a
shorter DFI interval, indicating that P-gp expression may be
linked to a more aggressive and malignant phenotype. Such a
correlation between MDR1 expression and tumor invasiveness
has been documented for breast cancer (45). In one study, it was
suggested that MDR1 expression in breast carcinoma cells
serves mainly as a surrogate marker for drug resistance (46).
This postulation was based on an observed absence of functional
P-gp-mediated pump activity as measured by the rhodamine 123
efflux assay in immunohistochemically P-gp-positive tumor
cells. Another study reported that MDR1, in addition to its role
in drug transport, might play a drug efflux-independent anti-
apoptotic role through modulation of the sphingomyelin-cera-
mide apoptotic pathway (47). More compelling evidence for an
antiapoptotic role for MDR1 has been provided by a study
showing that MDR1 hyperexpression may affect ceramide pro-
duction and subsequently affect the expression of multiple
downstream target genes of ceramide (48). In conclusion,
MDR1 is likely to be involved in anthracycline efflux-mediated
resistance and may be involved in apoptosis-associated MDR as
well.
In summary, our study suggests that MDR1 is an important
predictor of poor prognosis in breast cancer patients receiving
chemotherapy as first-line treatment for recurrent disease. Fur-
thermore, high MDR1 expression in primary breast tumors may
be related to altered biological behavior of the tumor cells,
including a more aggressive phenotype resulting in resistance to
first-line chemotherapy of advanced metastatic disease. Apart
from MDR1, expression of the drug resistance genes BCRP,
LRP, and MRP1 may have some additional predictive value for
clinical outcome in breast cancer. Clearly, further investigations
are needed to confirm the conclusions from this exploratory
study.
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